重组人干扰素α-1b治疗轮状病毒性肠炎的疗效观察(1)
【摘要】 目的 观察重组人干扰素α-1b治疗轮状病毒性肠炎中的临床疗效。方法 120例轮状病毒性肠炎患儿， 随机分为治疗组与对照组， 各60例。对照组患儿采用双歧杆菌三联活菌、蒙脱石散及补液等综合治疗， 治疗组在对照组基础上加用重组人干扰素α-1b注射液治疗。比较两组患者退热及止泻时间、临床疗效、抗原转阴情况、随访结果、不良反应发生情况。结果 治疗组患儿退热、止泻时间分别为(1.78±0.69)、(3.28±1.32)d， 均明显短于对照组的(2.84±1.35)、(4.58±1.28)d， 差异有统计学意义( P<0.05)。治疗组患儿总有效率95.00%及抗原转阴率86.67%显著高于对照组的68.33%、48.33%， 差异有统计学意义( P<0.05)。两组均未见明显不良反应发生。结论 重组人干扰素α-1b治疗轮状病毒性肠炎， 可明显缩短疗程， 迅速改善症状， 且未出现明显不良反应， 值得临床推廣应用。
【关键词】 干扰素α-1b ;轮状病毒;肠炎;双歧杆菌三联活菌;蒙脱石散
DOI：10.14163/j.cnki.11-5547/r.2019.01.048
【Abstract】 Objective To observe the clinical efficacy of recombinant human interferon α-1b on the treatment of rotavirus enteritis. Methods A total of 120 rotavirus enteritis children were randomly divided into treatment group and control group， with 60 cases in each group. The control group received comprehensive treatment of Bifidobacterium triple live bacteria， montmorillonite powder and fluid replacement， and the treatment group received recombinant human interferon α-1b injection on the basis of the control group. Comparison were made on antipyretic and antidiarrheal time， clinical efficacy， antigen negative， follow-up results， occurrence of adverse reactions between the two groups. Results The treatment group had obviously shorter antipyretic and antidiarrheal time respectively as (1.78±0.69) and (3.28±1.32) d than(2.84±1.35) and (4.58±1.28) d in the control group， and the difference was statistically significant (P<0.05). The treatment group had significantly higher total effective rate as 95.00% and antigen negative rate as 86.67% than 68.33% and 48.33% in the control group， and their difference was statistically significant (P<0.05). There was no significant adverse reactions occurred in two groups. Conclusion Recombinant human interferon α-1b in the treatment of rotavirus enteritis can significantly shorten the course of treatment， rapidly improve symptoms with no obvious adverse reactions. So it is worthy of clinical promotion and application.
【Key words】 Interferon α-1b; Rotavirus; Enteritis; Bifidobacterium triple live bacteria; Montmorillonite powder
轮状病毒性肠炎是婴幼儿秋冬季节的常见病， 具有传染性和流行性， 好发于6个月～3岁的婴幼儿， 病原多为轮状病毒， 该病常合并脱水、酸中毒和电解质紊乱， 严重威胁小儿的生命健康。目前， 对轮状病毒缺乏有效的治疗， 为探讨有效的治疗方法， 近年来本科用重组人干扰素α-1b治疗轮状病毒性肠炎， 取得了显著疗效。现报告如下。
1 资料与方法
1. 1 一般资料 选择2016年9月～2017年12月本院收治的120例轮状病毒性肠炎患儿， 所有患儿均符合《中国腹泻病诊断治疗方案》诊断标准[1]， 入选患儿大便轮状病毒检测均为阳性。将120例患儿随机分为治疗组与对照组， 各60例。患儿年龄6个月～3岁。治疗组男34例， 女26例。对照组男32例， 女28例。两组患儿一般资料比较， 差异无统计学意义(P>0.05)， 具有可比性。, 百拇医药(周华)
【关键词】 干扰素α-1b ;轮状病毒;肠炎;双歧杆菌三联活菌;蒙脱石散
DOI：10.14163/j.cnki.11-5547/r.2019.01.048
【Abstract】 Objective To observe the clinical efficacy of recombinant human interferon α-1b on the treatment of rotavirus enteritis. Methods A total of 120 rotavirus enteritis children were randomly divided into treatment group and control group， with 60 cases in each group. The control group received comprehensive treatment of Bifidobacterium triple live bacteria， montmorillonite powder and fluid replacement， and the treatment group received recombinant human interferon α-1b injection on the basis of the control group. Comparison were made on antipyretic and antidiarrheal time， clinical efficacy， antigen negative， follow-up results， occurrence of adverse reactions between the two groups. Results The treatment group had obviously shorter antipyretic and antidiarrheal time respectively as (1.78±0.69) and (3.28±1.32) d than(2.84±1.35) and (4.58±1.28) d in the control group， and the difference was statistically significant (P<0.05). The treatment group had significantly higher total effective rate as 95.00% and antigen negative rate as 86.67% than 68.33% and 48.33% in the control group， and their difference was statistically significant (P<0.05). There was no significant adverse reactions occurred in two groups. Conclusion Recombinant human interferon α-1b in the treatment of rotavirus enteritis can significantly shorten the course of treatment， rapidly improve symptoms with no obvious adverse reactions. So it is worthy of clinical promotion and application.
【Key words】 Interferon α-1b; Rotavirus; Enteritis; Bifidobacterium triple live bacteria; Montmorillonite powder
轮状病毒性肠炎是婴幼儿秋冬季节的常见病， 具有传染性和流行性， 好发于6个月～3岁的婴幼儿， 病原多为轮状病毒， 该病常合并脱水、酸中毒和电解质紊乱， 严重威胁小儿的生命健康。目前， 对轮状病毒缺乏有效的治疗， 为探讨有效的治疗方法， 近年来本科用重组人干扰素α-1b治疗轮状病毒性肠炎， 取得了显著疗效。现报告如下。
1 资料与方法
1. 1 一般资料 选择2016年9月～2017年12月本院收治的120例轮状病毒性肠炎患儿， 所有患儿均符合《中国腹泻病诊断治疗方案》诊断标准[1]， 入选患儿大便轮状病毒检测均为阳性。将120例患儿随机分为治疗组与对照组， 各60例。患儿年龄6个月～3岁。治疗组男34例， 女26例。对照组男32例， 女28例。两组患儿一般资料比较， 差异无统计学意义(P>0.05)， 具有可比性。, 百拇医药(周华)